Cargando…

Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer immunotherapy, but secondary resistance (SR) and immune-related adverse events (irAEs) are significant clinical dilemmas. Although the gut microbiota is associated with ICI efficacy and irAEs, the knowledge of longitu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Yanlin, Shi, Qingya, Liu, Xinyu, Tang, Hao, Lu, Bo, Zhou, Qingyang, Xu, Yan, Chen, Minjiang, Zhao, Jing, Li, Yue, Qian, Jiaming, Wang, Mengzhao, Tan, Bei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126279/ https://www.ncbi.nlm.nih.gov/pubmed/37114123 http://dx.doi.org/10.3389/fonc.2023.1144534

Ejemplares similares

Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events
por: Liu, Xinyu, et al.
Publicado: (2023)

Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor‐associated myocarditis
por: Xu, Yan, et al.
Publicado: (2022)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Gut microbiota shed new light on the management of immune‐related adverse events
por: Tan, Bei, et al.
Publicado: (2022)

Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma
por: Chen, Minjiang, et al.
Publicado: (2023)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
por: Liu, Jia, et al.
Publicado: (2022)

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
por: Frankel, Arthur E., et al.
Publicado: (2019)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
por: Song, Peng, et al.
Publicado: (2020)

Risk factors for immune-related adverse events: what have we learned and what lies ahead?
por: Liu, Xiaoyan, et al.
Publicado: (2021)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
por: Si, Xiaoyan, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
por: Pezo, Rossanna C., et al.
Publicado: (2019)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Yifan, et al.
Publicado: (2023)

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China
por: Shi, Yuequan, et al.
Publicado: (2021)

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Cui, Tian-ming, et al.
Publicado: (2020)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
por: Zhou, Guanzhou, et al.
Publicado: (2022)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
por: Li, Yue, et al.
Publicado: (2020)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal anti-tumor immunity
por: Choi, Yongbin, et al.
Publicado: (2023)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
por: Choi, Juwhan, et al.
Publicado: (2020)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events
por: Kawahira, Machiko, et al.
Publicado: (2022)

P14 A rare adverse event of eosinophilic fasciitis secondary to immune checkpoint inhibitor therapy
por: Byravan, Swetha, et al.
Publicado: (2023)

Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors
por: Wang, Jian, et al.
Publicado: (2020)

Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
por: Vivarelli, Silvia, et al.
Publicado: (2021)

A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer
por: Kim, Esther, et al.
Publicado: (2021)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mss8holhib0920oa3i6c3pblcb